A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Study identifier: NCT01033292
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Iniparib (Sanofi Aventis)
- Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma
- Completion of only one previous course of chemotherapy which contained a platinum therapy, with resistance to that regimen.
- Measurable disease, defined by at least one lesion that can be accurately measured in at least one dimension.
Type of study:
Phase II study
BSI-201 in combination with gemcitabine and carboplatin.
Massachusetts Ceneral Hospital
Boston, Massachusetts, 02114
Contact: Michael Birrer, MD, PhD 617-724-8540 email@example.com
Contact: Maria Roche, NP 617-724-8540 firstname.lastname@example.org
Principal Investigator: Michael Birrer, MD, PhD
Page updated 08/31/11
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.